Altogether, silibinin can inhibit cancer hallmarks against NSCLC cells and also inhibited PD-L1 expression through EGFR-mediated PI3K/AKT and JAK2/STAT5 signaling mechanisms (Figure 7). This evidence concerns the gene EGFR and non-small cell lung carcinoma.